
-
Runners fly to North Korea for first post-Covid Pyongyang Marathon
-
Hamilton rubbishes claims he's lost faith in Ferrari
-
Nintendo Switch 2 sparks excitement despite high price
-
Sri Lanka's crackdown on dogs for India PM's visit sparks protest
-
S Korea police raise security levels ahead of impeachment verdict
-
China vows 'countermeasures' to sweeping new US tariffs
-
Trump jolts allies, foes and markets with tariff blitz
-
France says EU to target US online services after Trump tariffs
-
Tsunoda vows to bring 'something different' after Red Bull promotion
-
Verstappen not happy with Tsunoda-Lawson Red Bull swap
-
Experts accuse 54 top Nicaragua officials of grave abuses
-
Remains of 30th victim of Los Angeles fires found
-
EU to target US online services after Trump tariffs: France
-
How Trump's 'liberation day' tariffs will impact China
-
Malaysia suspends search for long-missing flight MH370
-
Search for long-missing flight MH370 suspended: Malaysia minister
-
Europe hits out at Trump tariffs, keeps door open for talks
-
Myanmar's junta chief to head to Bangkok summit as quake toll surpasses 3,000
-
Lawson vows to prove he belongs in F1 after shock of Red Bull axing
-
Australia sweats through hottest 12 months on record: official data
-
Livestock theft is central to jihadist economy in west Africa
-
South African artist champions hyenas in 'eco-queer' quest
-
Danish PM in 'unity' Greenland visit amid US takeover threats
-
Taiwan says US tariffs 'highly unreasonable'
-
Lawson says ruthless Red Bull axing was 'tough to hear'
-
Heat humble Celtics for sixth straight win, Thunder roll on
-
Trump escalates trade war with sweeping global tariffs
-
Japan says US tariffs 'extremely regrettable', may break WTO rules
-
South Koreans anxious, angry as court to rule on impeached president
-
Juve at in-form Roma with Champions League in the balance
-
Injuries put undermanned Bayern's title bid to the test
-
Ovechkin scores 892nd goal -- three away from Gretzky's NHL record
-
Australian former rugby star Petaia signs for NFL's Chargers
-
China says opposes new US tariffs, vows 'countermeasures'
-
Athletics world watching as 'Grand Slam Track' prepares for launch
-
Heat humble Celtics for sixth straight win, Cavs top Knicks
-
Quake-hit Myanmar's junta chief to head to Bangkok summit
-
New Spielberg, Nolan films teased at CinemaCon
-
Shaken NATO allies to meet Trump's top diplomat
-
Israel's Netanyahu arrives in Hungary, defying ICC warrant
-
Shiny and deadly, unexploded munitions a threat to Gaza children
-
Stocks tank, havens rally as Trump tariffs fan trade war
-
Altomare hangs on to tie defending champ Korda at LPGA Match Play
-
Paraguay gold rush leaves tea producers bitter
-
Health concerns swirl as Bolivian city drowns in rubbish
-
Syria says deadly Israeli strikes a 'blatant violation'
-
Financial markets tumble after Trump tariff announcement
-
Starbucks faces new hot spill lawsuits weeks after $50mn ruling
-
Europe riled, but plans cool-headed response to Trump's tariffs
-
'Shenmue' voted most influential video game ever in UK poll

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
O.Johnson--AMWN